Starling Oncology, Inc.
DFPH- Exchange
- OTC
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- SEC CIK
- 0001799191
In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Starling Oncology, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Of which not filed for Q2 2021 | Q2 2021 | Change |
|---|---|---|---|---|
| Holders | 50 | 1 | 53 | +4 |
| Shares | 26.2M | 61.7K | 21.6M | −4.51M (−17.3%) |
| Value | $260.6M | $615.0K | $214.7M | −$45.2M (−17.4%) |
1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (12)
Institutions that held Starling Oncology, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| 683 Capital Management, LLC | 715,963 | $7.12M | 0.35% |
| Weiss Asset Management LP | 623,542 | $6.20M | 0.17% |
| Bank of America Corp | 462,000 | $4.60M | 0.00% |
| Picton Mahoney Asset Management | 150,000 | $1.49M | 0.05% |
| D. E. Shaw & Co., Inc. | 124,360 | $1.24M | 0.00% |
| Saba Capital Management, L.P. | 95,685 | $951.0K | 0.04% |
| Fortress Investment Group LLC | 86,056 | $857.0K | 0.04% |
| Omni Partners US LLC | 69,099 | $688.0K | 0.03% |
| Aristeia Capital LLC | 62,500 | $622.0K | 0.01% |
| Nomura Holdings Inc | 33,500 | $333.0K | 0.00% |
| Goldman Sachs Group Inc | 16,772 | $167.0K | 0.00% |
| UBS Group AG | 889 | $9.00K | 0.00% |
Sold out (8)
Institutions that held Starling Oncology, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Element Capital Management LLC | 599,800 | $5.97M |
| Kepos Capital LP | 297,500 | $2.96M |
| Linden Advisors LP | 97,271 | $970.0K |
| Ramius Advisors LLC | 65,724 | $655.0K |
| Centiva Capital, LP | 26,207 | $261.0K |
| Citadel Advisors LLC | 14,448 | $144.0K |
| Centric Wealth Management | 10,000 | $100.0K |
| Tower Research Capital LLC (TRC) | 49 | $0 |
Not filed for Q2 2021 yet (1)
Institutions that held Starling Oncology, Inc. at the end of Q1 2021 and haven't filed a 13F for Q2 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Omni Partners LLP | 61,724 | $615.0K |